<DOC>
	<DOCNO>NCT02334579</DOCNO>
	<brief_summary>The purpose study find effect ( good bad ) highly focused radiation prostate cancer . The purpose evaluation see treatment cause few side effect standard treatment approach , evaluate effect treatment prostate tumor quality life time .</brief_summary>
	<brief_title>Stereotactic Body Radiotherapy Stage I-III Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Histologically proven prostate adenocarcinoma Clinical stage T1aT3 , N0Nx , M0Mx Patients belong one follow risk group : ( 1 ) LOW RISK : CS T1aT2a , Gleason 26 , PSA &lt; 10 , Nx0 , Mx0 ; ( 2 ) INTERMEDIATE RISK : CS T2b , Gleason ≤7 , PSA &lt; 20 , Nx0 , Mx0 , CS T1aT2b , Gleason 26 , PSA≥10 &amp; &lt; 20 , Nx0 , Mx0 , CS T1aT2b , Gleason 7 , PSA≤20 , Nx0 , Mx0 ; ( 3 ) HIGH RISK : CS T2cT3 , Gleason , PSA , CS T13 , Gleason ≥8 and/or PSA≥20 Karnofsky performance status 70100 Hormone therapy : include LHRH agonist ( e.g . leuprolide , goserelin , triptorelin ) , antagonist ( e.g . degarelix ) , peripheral blocker ( e.g . flutamide , bicalutamide , nilutamide ) , estrogens ( e.g . DES ) bilateral orchiectomy Low Intermediate risk group : hormone ablation two month prior enrollment , treatment High risk group : three hormone therapy regimens allow 5alpha reductase inhibitor ( e.g. , finasteride dutasteride ) allow Prior prostatectomy cryotherapy prostate Prior highdose radiotherapy prostate lower pelvis Implanted hardware material would prohibit appropriate treatment plan treatment delivery , investigator 's opinion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Radiation</keyword>
	<keyword>Stereotactic Radiosurgery</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Prostate Tumor</keyword>
	<keyword>Prostate Surgery</keyword>
	<keyword>CyberKnife</keyword>
</DOC>